secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001493152-26-000994
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce shareholders approve share issuance to investor and incentive plan increase
--------------------------------------------------------------------------------

- Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.
- Amendment to 2021 Omnibus Incentive Plan approved, increasing authorized shares from 121,457 to 721,457.
- Class I directors William Chang and Lee Rauch reelected; Chang: 518,597 for, Rauch: 516,907 for.
- Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226000994/0001493152-26-000994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226000994/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-000994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer